Introduction
As a hepatologist, I very much wish I have a crystal ball in my clinic such that I would be able to tell if the patient sitting right in front of me has liver fibrosis or not. This is because liver fibrosis is such a key component of essentially all chronic liver diseases. It is the formation of scar tissue in response to parenchymal injury secondary to chronic liver disease, for example, chronic hepatitis B (CHB) and C (CHC), non-alcoholic fatty liver disease (NAFLD) or alcoholism. The continuous and progressive replacement of hepatocytes by extracellular matrix and fibrous tissue leads to liver cirrhosis, which is a key risk factor for hepatocellular carcinoma (HCC). 1 Liver fibrosis also serves as an important treatment indication in various chronic liver diseases. Different international treatment guidelines mentioned that the severity of liver fibrosis should be considered, regardless of serum alanine aminotransferase (ALT) level, for starting antiviral treatment for CHB. 2, 3 There are now solid evidence supporting the fact that liver fibrosis is potentially reversible. 4 Therefore, it is important to diagnose and assess the severity of liver fibrosis in order to provide appropriate management in order to prevent further liver damage. This article focuses on the up-to-date non-invasive approaches for the diagnosis and assessment for liver fibrosis.
Physical modalities

Shear wave elastography
Transient elastography. Transient elastography (FibroScan ® , Echosens, Paris, France) assesses liver stiffness measurement (LSM) by transmitting shear wave followed by ultrasound wave through a probe putting on the skin overlying the liver parenchyma. The velocity of the shear wave passing through the liver parenchyma is calculated by Doppler technique. The higher the velocity, the stiffer the liver parenchyma is. As mentioned by the manufacturer, for an examination to be considered as reliable, it requires at least 10 successful attempts, and the ratio of interquartile range to median of those measurements should be less than 0.3.
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LSM reflects the degree of liver fibrosis. 6 It can even identify those with no or minimal fibrosis and differentiate them from those with severe fibrosis (Metavir F3) or cirrhosis (F4). 7 It is useful and accurate across different liver disease entities (e.g. CHB and CHC and autoimmune hepatitis). 8 Nonetheless, LSM by transient elastography is not as reliable in obese patients. 9, 10 It may also be less accurate in certain situation, for example, severe acute exacerbation of hepatitis 11 and post-treatment fibrosis stages in CHB 12 or CHC patients. 13 One of the challenges of the clinical application of transient elastography is the increase in failure rate among obese subjects. 10 This challenges has been mostly tackled by the introduction of XL probe. 14, 15 Recently, spleen stiffness measurement with the same machine was found accurate in predicting portal hypertension and esophageal varices. 16, 17 Point shear wave elastography. When an acoustic radiation force impulse (ARFI) is applied at a depth within tissue, a shear wave is generated. It is implemented in current ultrasound scanner, without acquirement of external equipment. The conventional ultrasound probe automatically produces an acoustic "push" pulse for generating shear wave, which passes through the tissue. The wave propagation speed is assessed. Again, higher the speed, higher the LSM is. 18, 19 There are several advantages for ARFI. As it is a function of the ultrasound scanner, no additional cost is required. 20 The ARFI not only shows the degree of fibrosis but also provides external information for disease progression for different chronic liver disease, for example, HCV. 21 Another advantage of this tool is that it can provide real-time results and is easy to perform. The measurement results appear to be more accurate in overweight and obese patients, compared with transient elastography. 22 Virtual touch quantification (VTQ ® ), one of the ARFI-based techniques by different manufacturers, the availability of point shear wave elastography (SWE) ARFI-based technique on their ultrasound systems, gives values in m/s, whereas transient elastography gives values in kPa; to convert m/s in kPa, the Young modulus is used: 3 × density × velocity, 2 assuming that the tissue is a linearly elastic, homogeneous, isotropic medium. 23 Furthermore, it is quite difficult to match the degree of fibrosis with the wave propagation speed, that is, a cut-off, which is difficult to be defined. 24 Multidimensional shear wave elastography (twodimensional shear wave elastography and three-dimensional shear wave elastography). The method described earlier for point SWE may be extended to make quantitative images of shear wave speed in a large region of interest by placing the ARFI focus (push) at multiple sequential locations and, at each, detecting the shear wave arrival time at multiple lateral locations. 2D-SWE is a two-dimensional ultrasound technique based on the estimation of shear wave velocity from the radiation force of a focused beam of ultrasound, 25 and it can be converted results in terms of kPa by an equation. 26 No extra vibrator or detector is required as it is integrated into a conventional ultrasound system. Besides, elasticity of liver tissues can be shown in both numerical values and color (i.e. higher stiffness is reflected in red color), which can reflect the relative stiffness of the liver tissue quickly. The numerical values can be expressed in either kPa or m/s, which can be comparable with the results from transient elastography or VTQ. 27 Actually, its accuracy is higher compared with transient elastography or ARFI in assessing the degree of fibrosis, especially in those with early stage liver fibrosis.
28 SWE with spleen stiffness index is recommended as the first-line assessment for patients with liver fibrosis because of CHC in the latest guidelines. 29 However, only a few studies validate its clinical application. 28, 30 Magnetic resonance elastography. Magnetic resonance elastography (MRE) adopts a phase contrast imaging method, which depends on mechanical wave propagation to assess the degree of liver stiffness. 31 Generally, MRE is less operator dependent and involved in less technical failure. The global picture of the liver can be viewed easily, regardless the obesity or severity of the ascites of the patients. It can also give a comprehensive assessment for the associated complications, for example, portal hypertension or associated spleen stiffness. 32 Meanwhile, it is useful for diagnosis and staging of liver fibrosis, even if the fibrosis is very mild. Another advantage for MRE is that the results are readily reproducible. 32 However, MRE is more expensive and timeconsuming compared with ultrasound-based approach. Respiration creates artifacts on the images. Another important limitation is that it is not applicable on patients with iron overload, or hemochromatosis, because iron might create noise for the signals received by the magnetic resonance machine. 33 There are still limited studies mentioning the clinical significance of MRE results. Even though it is apparently sensitive to mild liver fibrosis, the result may sometimes be unreliable. 34 
Serum test formulae
Common laboratory parameters. Another commonly adopted non-invasive assessment is based on serum with or without clinical parameters. Examples including common parameters in clinical practice include aspartate aminotransferase to platelet ratio index (APRI), 35 Forns index, 36 fibrosis-4, 37 FibroIndex, 38 Hui index, 39 NAFLD fibrosis score, 40 and BMI, Age, ALT, triglyceride (BAAT) score 41 (Table 1) . These parameters are derived from routine liver biochemistry panel, so it is quite convenient. These parameters are also technically easy to obtain and with minimal interobserver variations. Patients with advanced fibrosis can be identified by these tests. 42 However, these parameters are often validated in just one or two liver diseases. For example, two scoring systems for CHC patients, namely, APRI and fibrosis-4, are found to be not useful in CHB patients. 43 
FibroTest
® . Some specific biochemical parameters related to fibrinolysis or fibrinogenesis are developed to improve the specificity of liver fibrosis assessment. One example is FibroTest (BioPredictive, Paris, France, or FibroSure ® by LabCorp, Burlington, NC, USA) consists of five components, namely, gamma-glutamyl transferase, total bilirubin, α-2 macroglobulin, apolipoprotein A1, and haptoglobin. Sometimes, another test, ActiTest ® , would also be performed together with FibroTest for assessment for liver activity, with the additional measurement of ALT. The results would be adjusted according to age and gender. 
GL-H Wong Assessments for liver fibrosis
Nowadays, it is recommended by different associations concerning liver studies for evaluation of liver fibrosis in patients with CHB, NAFLD, or alcoholic liver disease. [45] [46] [47] It is highly reliable and applicable, even for patients with obesity. 48 It performs well for diagnosis of liver cirrhosis for disease entities other than CHC. However, the results are suboptimal for detecting earlier stages before cirrhosis. 49 
FibroMeter
® . FibroMeter (Echosens, Paris, France) has been validated in patients with CHB, CHC, NAFLD, and alcoholic liver disease. 50 Platelets, prothrombin index, aspartate aminotransferase, α-2 macroglobulin, hyaluronate, urea, and age are taken into account. 51 Second generation has put age into another important parameter. 50 FibroMeter has recently reached its third generation, which does not take hyaluronate into account. Therefore, the cost has been reduced but with similar effectiveness. 52 FibroMeter, both second generation and third generation, has been shown with high fibrosis classification accuracy. 53 Besides, it appears to have a good predictive value towards the occurrence of severe fibrosis in those with NAFLD 54 and CHB or CHC. 55 Enhanced liver fibrosis. Enhanced liver fibrosis (ELF) score is an algorithm consists of three direct markers in blood, namely, procollagen III amino terminal peptide, hyaluronic acid, and tissue inhibitor of metalloproteinase I. 56 ELF can be a good prognostic factor for the clinical outcomes of patients with chronic liver disease. The increase in one point in ELF can lead to doubling of the risk of clinical outcomes in patients, especially liver-related clinical outcomes. 57 It is sensitive in identifying advanced fibrosis or cirrhosis but not for lower fibrosis stage. 58 Meanwhile, it is noted that different factors can influence the result of ELF score, with the most significant factor being age. 59 Other factors include low CD4+ T-cell count and coexisting extrahepatic fibrosis. 60 Therefore, the results of ELF should be interpreted with particular clinical context.
Novel serum markers.
There are some other novel serum fibrosis markers that raise the attention of the clinicians. Glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein is a marker, which is related to fibrosis-related glyco-alteration. It can be measured by a glycan-based immunoassay, FastLec-Hepa. A cut-off index would be calculated based on the measured value. 61 Another novel marker, YKL-40 (CHI3L1), is an emerging inflammation biomarker, which was shown to be related to the early stage of liver fibrosis. 62 However, further studies need to be conducted to show the effectiveness and impact of both biomarkers on making the diagnosis or management of patients with liver fibrosis due to any chronic liver diseases.
Two are better than one-combination of different approaches. It is common for using both physical and biochemical methods to increase the accuracy in determining the degree of fibrosis. Both types of methods can play a supplementary role to each other. For example, the use of ELF-LSM algorithm, a significant proportion of patients can avoid liver biopsy. 56 Another example is Hui index and transient elastography. Because LSM result is confounded in patients with elevated ALT, Hui index, a score independent of ALT level, is a good choice for supplementation of transient elastography. Studies have shown that the combinations can help predict hepatic event-free survival in CHB patients. 63 Another combination for assessment of liver fibrosis in CHB patients is Forns index (another ALT-free index)-LSM algorithm. 64 For the diagnosis of cirrhosis in CHC patients, using the algorithm FibroTest and transient elastography improves the performance. However, this combination does not show extra benefit for diagnosis of advanced fibrosis compared with the sole use of FibroTest. 65 Non-invasive assessment-it is more than just diagnostic and also prognostic Portal hypertension and related complications. The role of all these non-invasive assessments is moving from diagnostic to prognostic. They are useful to predict various liver-related complications and hence the prognosis of patients with chronic liver diseases. Assessment of spleen loss modulus by MRE is a good method for recognizing patients with severe portal hypertension or esophageal varices with high bleeding tendency. 66 Combing LSM and spleen stiffness measurement may exclude the presence of large esophageal varices with high sensitivity 67 and can be adopted in the risk stratification and variceal screening strategy but saving cost and risk from upper endoscopy examination without missing clinically significant varices. 17, 68 LSM-spleen diameter-to-platelet ratio index is another reliable predictor for the risk of variceal bleeding; prophylactic treatments should be 2D-SWE, two-dimensional shear wave elastography; 3D-SWE, three-dimensional shear wave elastography; 3G, third generation; ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet ratio index; AST, aspartate aminotransferase; CAP, controlled attenuation parameter; CHB, chronic hepatitis B; CHC, chronic hepatitis C; ELF, enhanced liver fibrosis; FIB-4, fibrosis-4; GGT, gamma-glutamyl transferase; pSWE, point shear wave elastography.
considered for subgroups with LSM-spleen diameter-to-platelet ratio index ≥ 6.5.
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Survival. Survival for chronic liver disease can be predicted using non-invasive test. LSM 70 or FibroTest has a high prognostic value for patients with chronic viral hepatitis. 71 Applying LSM and Hui index for predicting hepatic event-free survival in CHB patients is shown to be accurate. 63 FibroMeter is shown to be useful for assessment of liver prognosis in CHC patients with milder disease. 72 ELF score can be used to assess the prognosis of patients with different chronic liver diseases. 57 Hepatocellular carcinoma. There is a strong predictive and even diagnostic role of the non-invasive tests for HCC. ARFI is used for differentiating benign and malignant liver tumors by the assessment of virtual touch tissue imaging (VTI) and VTQ, as virtual touch tissue imaging appears to be stiffer and VTQ is higher in malignant lesion than its benign counterpart. 73 For MRE, the measurement of loss modulus in liver tumor can help differentiating the benign lesions from the malignant ones, with the former having a lower value. 74 Non-invasive test is also an important part of some HCC risk score. For example, LSM-HCC score, which is optimized from CU-HCC score with LSM, further increases the negative predictive value to close to 100% for HCC prediction in 3 to 5 years in CHB patients. 75 Both FibroTest and LSM results can help predict the occurrence of HCC in patients with viral hepatitis. 76 Non-invasive tests can also play some part in prognosis of HCC. For example, in HCC patients receiving partial hepatectomy or transarterial chemoembolization, LSM and APRI are an independent prognostic factor. [77] [78] [79] LSM is also found useful to predict de novo recurrence after curative treatment (e.g. resection 80 or radiofrequency ablation 81, 82 ) for HCC.
Conclusion
With the wide applicability of non-invasive assessments of liver fibrosis, the management of two billion patients with chronic liver diseases worldwide has been revolutionized. While liver biopsy examination still has an important role in the diagnostic process, non-invasive assessments including transient elastography and serum biomarkers have high accuracy to diagnose advanced fibrosis and cirrhosis. Transient elastography and serum biomarkers can be used alone or in combination, either simultaneously or in a stepwise approach. If all these tools can be further optimized by improving the accuracy and with most of the confounding factors handled, having one of such tools in my clinic is perhaps just as good as having a crystal ball there.
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